Grifols (GRFS) Income from Non-Controlling Interests (2010 - 2023)
Grifols (GRFS) reported Income from Non-Controlling Interests of $130569.6 for Q4 2023, up 103.57% on a YoY basis from $64139.9 in Q4 2022, and up 103.57% quarter-over-quarter from $64139.9 in Q4 2022.
Grifols (GRFS) Income from Non-Controlling Interests (2010 - 2023) Analysis & Trends
Grifols has reported Income from Non-Controlling Interests for 12 years, with the latest figure at $130569.6 in Q4 2023.
- For the quarter ending Q4 2023, Income from Non-Controlling Interests rose 103.57% year-over-year to $130569.6; the trailing twelve-month figure through Dec 2023 stood at -$18.6 million (down 11.57% YoY), and the FY2025 full-year result was $114.1 million, up 90.63% from the prior year.
- Income from Non-Controlling Interests for Q4 2023 stood at $130569.6, up from $64139.9 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $130569.6 in Q4 2023, with the low at -$18.9 million in Q1 2020.
- Historically, Income from Non-Controlling Interests has averaged -$4.7 million across 4 years, with a median of $82649.9 in 2019.
- Annual changes were most pronounced in 2019 — Income from Non-Controlling Interests soared 115.33% — and 2020, when it sank 18826.37%.
- Grifols' Income from Non-Controlling Interests stood at $101160.0 in 2019, then slumped by 18826.37% to -$18.9 million in 2020, then jumped by 100.34% to $64139.9 in 2022, then jumped by 103.57% to $130569.6 in 2023.
- The last three Income from Non-Controlling Interests figures came in at $130569.6 (Q4 2023), $64139.9 (Q4 2022), and -$18.9 million (Q1 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.48 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 2.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.00 Mn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 130,569.61 |
| Dec 31, 2022 | 64,139.89 |
| Mar 31, 2020 | -18.94 Mn |
| Mar 31, 2019 | 101,159.97 |
| Dec 31, 2018 | 2.06 Mn |
| Jun 30, 2018 | 668,328.87 |
| Mar 31, 2018 | -659,722.11 |
| Dec 31, 2017 | -1.22 Mn |
| Jun 30, 2017 | 256,194.99 |
| Mar 31, 2017 | -274,874.98 |
| Dec 31, 2016 | -353,069.82 |
| Sep 30, 2016 | 256,722.43 |
| Jun 30, 2016 | 76,831.50 |
| Dec 31, 2015 | -1.98 Mn |
| Sep 30, 2015 | 201,323.57 |
| Jun 30, 2015 | 523,836.96 |
| Mar 31, 2015 | -754,728.11 |
| Sep 30, 2013 | 967,278.17 |
| Jun 30, 2013 | 1.19 Mn |
| Mar 31, 2013 | 1.92 Mn |